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The importance of correctly timing cancer immunotherapy
Elham Beyranvand Nejada,b*, Marij J.P. Weltersa*, Ramon Arensb and Sjoerd H. van der Burga
aDepartment of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands; bDepartment of Immunohematology and Blood
Transfusion, Leiden University Medical Center, Leiden, The Netherlands
ABSTRACT
Introduction: The treatment options for cancer—surgery, radiotherapy and chemotherapy—are now
supplemented with immunotherapy. Previously underappreciated but now gaining strong interest are
the immune modulatory properties of the three conventional modalities. Moreover, there is a better
understanding of the needs and potential of the different immune therapeutic platforms. Key to
improved treatment will be the combinations of modalities that complete each other’s shortcomings.
Area covered: Tumor-specific T-cells are required for optimal immunotherapy. In this review, the
authors focus on the correct timing of different types of chemotherapeutic agents or immune mod-
ulators and immunotherapeutic drugs, not only for the activation and expansion of tumor-specific T-
cells but also to support and enhance their anti-tumor efficacy.
Expert opinion: At an early phase of disease, clinical success can be obtained using single treatment
modalities but at later disease stages, combinations of several modalities are required. The gain in
success is determined by a thorough understanding of the direct and indirect immune effects of the
modalities used. Profound knowledge of these effects requires optimal tuning of immunomonitoring.
This will guide the appropriate combination of treatments and allow for correct sequencing the order
and interval of the different therapeutic modalities.
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The common treatment options for cancer patients so far were
surgery, radiotherapy and/or chemotherapy. This is now sup-
plemented with a fourth treatment modality that is called
immunotherapy. The latter encompasses several strategies
aiming to reinforce the immune system’s attack of tumor
cells by activation of tumor-specific lymphocytes, alleviation
of immune suppressive mechanisms and stimulation of
immune effector cell infiltration. Prime examples are vaccina-
tion strategies and the adoptive transfer of expanded tumor
infiltrating (T-cell receptor engineered or re-educated) lym-
phocytes to increase the number of tumor-specific T-cells
required to control tumor cell growth [1,2]. For instance, a
synthetic long peptide (SLP) vaccination against human papil-
lomavirus type 16 (HPV16) resulted in complete clearance of
HPV16-induced high-grade premalignant lesions of the vulva
in ~50% of the patients [3,4]. Importantly, prolonged survival
was found in patients treated with the food and drug admin-
istration (FDA) approved autologous cellular vaccine sipuleu-
cel-T for castration-resistant prostate cancer [5]. Furthermore,
adoptive transfer of autologous T-cells resulted in clinical
objective responses in half of the treated melanoma patients
[6,7]. Moreover, cancer regression and improved survival has
been achieved in melanoma and lung cancer patients using
antibodies to coinhibitory molecules, including anticytotoxic
T-lymphocyte-associated protein 4 (CTLA-4; ipilumimab,
tremelimumab) antibodies [8,9], antiprogrammed cell death
protein 1 (anti-PD-1; nivolumab, pembrolizumab) antibodies
[10–13] and antiprogrammed death-ligand 1 (anti-PD-L1; ave-
lumab, atezolizumab; durvalumab) antibodies [14–17]. Clinical
success has also been achieved using targeted therapies aim-
ing to inhibit molecular pathways that are important for tumor
growth and maintenance, either as a single therapy or in
combination with immunotherapeutic strategies [18]. In addi-
tion, epigenetic drugs to upregulate immune signaling com-
bined with immunotherapy are currently under investigation
[19,20], but this is beyond the scope of the current review.
In spite of all the mentioned immunotherapeutic strategies,
there are still numerous cancer patients who do not benefit
from these immunotherapeutic drugs. Monotherapy, although
successful in a number of cases, is not expected to have a
major impact as established tumors use diverse strategies to
evade the immune system, a process that is called immunoe-
diting [2,21,22]. Under the attack of the immune system,
tumor cells may alter the processes involved in the presenta-
tion of antigens to T-cells (i.e. downregulation of major histo-
compatibility complex (MHC) class I, epigenetic silencing of
the antigen processing machinery, loss of tumor associated-
antigens) or become more resistant to immune mediated
effector mechanisms leading to growth arrest and cell death
[2]. Furthermore, the tumor microenvironment may become
more immunosuppressive by the attraction and/or induction
of suppressive immune cells, i.e. regulatory T-cells (Tregs),
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myeloid-derived suppressor cells (MDSCs), type 2 macro-
phages (M2) [2,23]. This process leads to a less efficient anti-
tumor response. Therefore, there is tremendous demand to
develop cancer immunotherapies not only to activate the
tumor-specific T-cell response but also to strengthen its force
by combatting the immune evasion and suppressive pathways
to improve the clinical outcome [2,21,22]. Based on these
concepts, wise choices for complementary and synergistic
combinations of immunotherapeutic drugs have to be made.
Importantly, combinations with more conventional treatments
should not be discarded. This selection entails a thorough
understanding of the immune-modulating and pharmacologi-
cal properties as well as the limitations of the agents of choice.
Together, this should guide the right combination, dose, and
treatment schedule and lead to optimal treatment strategies.
Here we provide an overview of the current literature on
the timing of therapeutic vaccination in cancer patients. First,
timing applies to the most appropriate stage of disease in
which an immunotherapeutic modality can be used for opti-
mal clinical effects. Second, timing concerns the sequence and
interval of a combination of drugs for immunotherapy.
2. Immunotherapy efficacy at various stages of the
disease
2.1. Treatment of advanced or end-stage cancer may fail
due to immune suppression
Immunotherapy is often tested in advanced or end-stage
cancer patients. These patients have lost responsiveness to
earlier therapies, the tumor has grown to larger extent and
general immune suppression is more pronounced [2,21]. In
preclinical mouse models this is reflected by the increasing
failure to control tumor outgrowth when the time period
between tumor engraftment and vaccination is increased.
This is mainly due to increased frequencies of Tregs and
myeloid suppressor cells [24]. In the human setting this is
exemplified by the many vaccine trials that have failed to
show an effect [2]. Thus, in these late stages the tumor
micro-milieu may frustrate the effector arm of the immune
system through different mechanisms. First of all, the influx of
tumor-specific T-cells may be hampered by abnormal
vascularization [25,26]. In both a xenograft transplant model
and an immune refractory spontaneous murine model this
problem could be overcome by treatment with low dose of
gamma irradiation [25], or by targeting VEGF (vascular
endothelial growth factor) [27]. However, even when the effec-
tor cells are inside the tumor they may encounter several
immune suppressive hurdles before they can reach and kill
the tumor cells [28]. The tumor micro-environment contains
cells that are helping the tumor to expand and to evade the
immune system such as cancer-associated fibroblasts, MDSCs,
M2 and Tregs [29]. The important role of macrophages in
tumor progression and the possibilities to target these cells
were reviewed previously [30,31]. Targeting these tumor-resi-
dent immune suppressive myeloid cells could be an option to
improve immunotherapy [30–32]. Hence, it is no surprise that
specifically mono-immunotherapy – focused on reinforcing
the tumor-specific T-cell response – as a last resort therapy is
often not successful.
2.2. Success of therapy at early stages of cancer or
minimal residual disease
Better clinical outcomes are expected if one can treat patients
before recurrences develop, in settings of minimal residual
disease, or at early (premalignant) stages of disease. Indeed,
as shown in two independent trials, HPV16-SLP vaccination of
patients with high-grade premalignant lesions of the vulva
resulted in complete regressions of the lesion in almost half
of the treated patients [3,33]. Vaccination with a HPV16 E6-E7-
L2 fusion protein vaccine in combination with Aldara treat-
ment also achieved clinical success in patients with this dis-
ease [34]. Moreover, treatment of high-grade premalignant
lesions of the cervix was efficacious when the patients
received a DNA vaccine targeting the HPV16 oncoproteins
[35]. Moreover, vaccination of patients with HER+ breast ductal
carcinoma in situ resulted in measurable decreases of residual
ductal carcinoma [36]. As can be deduced from above, resec-
tion of the tumor mass may alleviate immune suppression
allowing the use of immunotherapy to prevent new tumors
to arise. Indeed, vaccination of patients with completely
resected colorectal cancer metastases showed a significant
survival advantage when compared to controls [37], whereas
HER2 peptide vaccination in disease-free breast cancer
patients was associated with a favourable trend for lower
recurrences [38]. Unfortunately, this is not always the case as
exemplified by a recent report on patients with surgically
resected early stage non-small-cell lung cancer whom were
vaccinated with MAGE-A3 but failed to show any improve-
ment in disease free survival [39,40].
2.3. Prevention of cancer for patients at risk
Vaccination of individuals to prevent disease has been one of
the major achievements in mankind. Current data on the
preventive vaccines for cervical cancer and liver cancer sup-
port the notion that prevention is key to success [41,42]. Also
for non-virally induced cancers, vaccine strategies are being
developed for individuals who are at risk to develop cancer.
For instance for individuals with BRCA mutations known to
Article highlights
● A profound understanding of the immune modulatory effects of
current cancer therapies allows finding the optimal timing of multiple
therapies with most clinical benefit for the cancer patient.
● Single treatment modalities can be successful at an early phase of
disease while at later disease stages combinations of several mod-
alities are required.
● Therapies applied before therapeutic vaccination are generally aimed
at alleviation of immune suppression.
● Therapies provided concurrently or shortly after vaccination aim to
potentiate the vaccine-induced immune response and to prevent
normal immune regulation.
● Harmonization of immune monitoring helps paving the way for the
rational design of immunotherapeutic combination strategies.
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induce breast cancer or for those with Lynch syndrome which
is associated with colon cancer [43]. Certainly, there are no
cancer-associated hurdles to be overcome when a person is
still healthy. This allows the vaccine to induce a protective
immune response against the tumor antigens expressed by
the type of cancer for which they are at risk [44]. Awareness of
the regulatory authorities for this approach is very important
to successfully combat cancer [45].
3. Correctly timing of therapeutic vaccination in
combination with other therapies
Therapeutic vaccination in combination with other therapies
can roughly be divided into three differently timed treatment
schedules. Treatments that are given before vaccination are
generally aimed at removing tumor-associated immune sup-
pression. Modalities provided close to or in combination with
vaccination aim to prevent immune regulation following T-cell
activation, thereby improving the quality and efficacy of the
vaccine-induced T-cell response. Therapies provided after vac-
cination generally are to boost the T-cell stimulatory effect of
the vaccine or their effector function. An overview of such
studies is provided in Table 1.
3.1. Combinations of therapeutic modalities prior to
vaccination
3.1.1. Administration of chemotherapy before vaccination
alleviates immune suppression
It is known that both local and systemic immune parameters
in patients with cancer are associated with the prognosis and
response to therapy [93]. The composition, phenotype and
activation status of the tumor infiltrating T-cells, DCs and
macrophages have a strong impact on clinical outcome. In
cancer patients with a higher tumor load, the tumor micro-
environment merely is pro-tumorigenic and suppressive for
the immune effector cells. In a number of cases this is also
reflected by the immune cell markers and function of immune
cells in the blood of these patients, as measured by flow
cytometry and/or functional immune assays [94,95].
Chemotherapy, radiotherapy and surgery used for the treat-
ment of cancer are applied for tumor reduction or eradication.
As a direct result they will remove cancer-derived factors known
to induce immune suppression. However, even when unsuc-
cessful as monotherapy, a number of chemotherapeutic com-
pounds may also have direct effects on the immune system
[96,97], albeit that for many of these compounds the underlying
mechanisms still remain to be elucidated. In HPV16+ TC-1 tumor
bearing mice and in advanced stage or recurrent HPV16+ cervi-
cal carcinoma patients the number of circulating myeloid cells,
including immunosuppressive myeloid cells, is significantly
increased when compared to naïve mice and healthy indivi-
duals, respectively [48]. The standard chemotherapy treatment
(carboplatin combined with paclitaxel) for these advanced can-
cer patients resulted in normalization of the different myeloid
cells in the peripheral blood, starting 2 weeks after the second
chemotherapy cycle and coinciding with a stronger general
T-cell response and improved antigen presenting capacity. As
this chemotherapeutic treatment not only normalized the
circulating myeloid cell population in mice but also altered
the intratumoral myeloid cell composition and increased the
clinical effect of therapeutic vaccination, it is believed that this
will also result in a reduced suppressive microenvironment in
patients. Indeed, a single vaccination with HPV16-SLP within the
correct time window of 2 weeks after the second cycle of
chemotherapy resulted in a much stronger HPV-specific T-cell
response than observed before, when vaccination was given
after chemotherapy failure [4,48]. In line with this data, a similar
time window of 12–14 days after combination chemotherapy
with carboplatin and paclitaxel has been observed in a study of
advanced ovarian cancer patients [47]. Here, they reported that
at this time point the number of Tregs was reduced while there
were increased percentages of IFNγ-producing CD8+ T-cells,
T-helper (Th1) cells, CD45RO memory T-cells and NKT-cells.
Also in extensive stage small cell lung cancer, vaccination with
DCs transduced with full-length wild-type p53 gene delivered
via an adenoviral vector at least 8 weeks after the last dose of
chemotherapy with carboplatin or cisplatin demonstrated a
high rate of objective clinical responses, and this was associated
with the induction of vaccine-induced immune responses [46].
An effect on the number and function of Tregs has specifi-
cally been reported for the chemotherapeutic agent cyclopho-
sphamide [98,99]. Several studies suggest that the optimal time
point for vaccination is 3–7 days after this type of chemotherapy
[50–52]. In a randomized phase II trial, administration of a single
dose of cyclophosphamide, followed by vaccination 3 days later
with IMA901, a vaccine that consists of multiple-tumor asso-
ciated peptides (TUMAPs) plus granulocyte-macrophage col-
ony-stimulating factor (GM-CSF), reduced the number of Tregs
and was associated with prolonged survival in immune respon-
der patients with advanced renal cell cancer [52]. Similarly,
peripheral blood mononuclear cells (PBMCs) analysis of stage
II–III melanoma patients, who were vaccinated with HLA-
A*0201-modified tumor peptides 7 days after low-dose of cyclo-
phosphamide, showed transient reduction in the frequency of
Tregs and an increase in vaccine-induced antigen specific CD8+
T-cells [50]. Other studies in which cyclophosphamide treatment
was used, showed that the depletion of Tregs may be associated
with the induction of Th17, Th1 and vaccine-induced
CD25+CD4+Foxp3-negative effector T-cells [65,66]. Also other
chemotherapeutic compounds may affect Tregs and immune
suppressive myeloid cells. Gemcitabine is known to reduce both
Tregs and MDSCs in mice and in patients with ovarian cancer
[53,54,80,100,101]. A selective decrease in MDSCs was also
observed after treatment with 5-fluorouracil (5-FU) [102]. The
combination of cisplatin plus vinorelbine appears to significantly
increase the ratio between effector T-cells and Tregs and to
reduce the immunosuppressive activity of the latter in the
blood of the majority of non-small cell lung cancer patients
[103]. Therefore, modulation of immune suppressive cells by
chemotherapeutic agents prior to anticancer vaccine could
explain the additive or synergistic antitumor effect of combined
chemotherapy and immunotherapy.
3.1.2. Other interventions applied before vaccination that
reduce immune suppression
Notably, the reduction of immunosuppressive cells can also be
mediated by other methods than chemotherapy. These





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































EXPERT OPINION ON BIOLOGICAL THERAPY 93
therapies should also be provided prior to administration of
immunotherapy or at the time that immunotherapy induces
tumor-specific immune responses [104,105]. For instance, in
the CT26 tumor model the antibody mediated depletion of
CD25+ T-cells (including Tregs) before immunization with
tumor antigen AH1 resulted in long-lasting memory T-cell
responses and even augmented a tumor-induced CD4+ T-cell
response [56]. In another study, vaccination with AH1 tumor
antigen in combination with the FOXP3-binding P60 peptide,
which reduces the suppressive function of Tregs by prevent-
ing the nuclear translocation of FOXP3 and thus its ability to
suppress the transcription factor NF-κB and NFAT, efficiently
protected mice against CT26 tumor growth [106]. Likewise,
antibody-mediated depletion of CD4+ CD25+ Tregs before
vaccination with DCs loaded with tumor cells, that had been
stressed by heat shock and irradiation, resulted in a delayed
tumor outgrowth and long-lived tumor-protective immune
responses [57]. Also depletion of CD25+ Tregs prior to tumor
cell-based vaccination and CTLA-4 blocking, enhanced the
TRP-2-specific CD8+ cytotoxic T lymphocyte (CTL) response in
B16 melanoma tumor model [55]. Similarly , application of the
CD25-blocking monoclonal antibody daclizumab to patients
with metastatic breast cancer, 1 week before multiple injec-
tions with a vaccine (consisting of three peptides derived from
human telomerase reverse transcriptase [hTERT], survivin, and
pp65 of cytomegalovirus [CMV] as a control), resulted in pro-
longed Treg suppression and robust vaccine-induced IFNγ-
producing T-cell responses [107]. However, Treg depletion by
using anti-CD25 antibodies may also be performed at the
same time with the administration of the vaccine [108]. The
elimination of CD4+ CD25+ Tregs by using denileukin diftitox,
a diphtheria toxin fragment conjugated to recombinant IL-2
(DAB389IL-2; also known as ONTAK) that is rapidly internalized
upon binding to the IL-2 receptor and then releases the
apoptosis inducing toxin, significantly enhanced a tumor
RNA-transfected DC vaccine-induced tumor-specific T-cell
response in renal cell carcinoma (RCC) patients [60].
Small molecule inhibitors were also shown to decrease
immune suppression [73]. In a murine colon carcinoma
(MC38-CEA) sequential administration of sunitinib, a tyrosine
kinase inhibitor, followed by a poxvirus-based vaccine encod-
ing carcinoembryonic antigen (CEA) plus three costimulatory
molecules (B7-1, ICAM-1 and LFA-3) resulted in decreased
numbers of intratumoral Tregs and MDSCs as well as an
increased influx of antigen-specific T-cells, with as conse-
quence a better tumor control and prolonged survival [72].
Last but not least, low-dose total body irradiation therapy also
reduced Tregs and increased effector-memory T-cell frequen-
cies. Administration of a DC-gp100 tumor vaccine 11 days
after low dose irradiation reduced tumor outgrowth and
increased survival of melanoma-bearing mice [49]. Taken
together, altering Treg function or depleting Tregs may
improve tumor-specific immune responses and expand the
efficacy of immunotherapy (reviewed in [105]).
As already eluded to in the above section, some modalities
may also affect MDSC or M2 function and number [109].
However, others are specifically designed to impact on mye-
loid cells. For instance, the CSF-1 receptor (CSF-1R) is a key
regulator for monocyte differentiation from progenitors of the
bone marrow and for monocyte activation and migration. It
has been shown that macrophages induction by CSF-1 could
lead to polarization towards an immunosuppressive and
tumor-promoting phenotype [110]. Blocking of CSF-1R signal-
ing by using recombinant CSF-1 antibodies against the ligand
and the receptor, or specific inhibitors of the CSF-1R kinase
activity might be effective in combination with other immu-
notherapies. In the B16F10 mouse melanoma model, inhibi-
tion of CSF-1R (PLX3397 kinase) in combination with CD8
T cell-mediated immunotherapy, consisting of the transfusion
of pmel-1 CD8+ T-cells and peptide vaccination, could effi-
ciently remove intratumoral F4/80+ macrophages, increase
IFNγ production of tumor-specific CD8+ T-cells and delay
tumor outgrowth [58]. In another study, PLX3397 given
4 days before adoptive T-cell therapy improved the efficacy
of this immunotherapy in a syngeneic mouse model of BRAF
(V600E)-driven melanoma by decreasing tumor-infiltrating
myeloid cells, skewing macrophages towards MHCIIhi type 1
macrophages (M1) and by increasing the number of IFNγ-
producing tumor-infiltrating lymphocytes (TIL) [59].
Therefore, targeting myeloid cells either to prevent their
recruitment to the tumor or to inhibit their pro-tumor polar-
ization may foster immune control of tumor cells. Such a
strategy, used as a standalone therapy or in combination
with other immunotherapies has been shown successful to
enhance antitumor immune responses [109,111].
3.1.3. Chemoradiation applied prior to vaccination can
induce optimal T-cell responses
Chemotherapy not only acts through the alleviation of
immune suppression, but can also have beneficial effects on
the immune system through other mechanisms. For example,
cyclophosphamide also can induce the infiltration of immune
lymphocytes to the tumor as well as promote homeostatic
proliferation/activation of B and T lymphocytes due to a cyto-
kine storm (GM-CSF, IL-1B, IL-7, IL-15, IL-2, IL-21 and IFNα) after
drug-induced lymphodepletion [71]. Moreover, many other
immunomodulatory factors such as danger signals, pattern
recognition receptors, and chemokines receptors are upregu-
lated after cyclophosphamide treatment. These alterations
may explain the improved antitumor immunity observed
after cyclophosphamide treatment in those cases where an
overt effect of cyclophosphamide on the levels and function
of Tregs could not be detected [112,113]. The pharmacokinetic
analysis of gene and protein expression and anti-tumor effi-
cacy in different therapeutic regimens indicate that the opti-
mal time point to apply adoptive immunotherapy is 1 day
after cyclophosphamide treatment [65].
Above all, in cases where the treatment modalities stimu-
late the functionality or stability of tumor-specific CD8+ T-cells,
administration of immunotherapy following conventional
therapy can improve the antitumor immune responses
[63,67]. In an established 3LL lung tumor model, administra-
tion of docetaxel before but not after vaccination with a GM-
CSF-producing tumor vaccine could significantly induce tumor
regression and prolonged survival [63]. This is due to the
docetaxel-associated enhanced survival of activated antigen-
experienced T-cells induced by the vaccine over that of pre-
existing memory CD8+ T-cells and Tregs [63]. Similar results
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have been observed in melanoma patients who received
dacarbazine (DTIC) 1 day before tumor–antigen vaccination
[68]. Dacarbazine induces activation of genes involved in cyto-
kine production, leukocyte activation, immune response and
cell motility, thereby enhancing CD8+ memory T-cell response
[68]. It also broadens the TCR repertoire used and this is
accompanied by high T-cell avidity and tumor reactivity [69].
Furthermore, in a HPV-induced tumor model, vaccination with
HPV16 E6E7L2 fusion protein (TA-CIN) with GPI-0100 adjuvant
1 day after administration of cisplatin reduced tumor out-
growth and extended the survival of TC-1 tumor-bearing
mice compared to vaccination alone [70]. In similar studies,
cisplatin treatment of mice 4–7 days before vaccination with a
DNA vaccine encoding calreticulin linked to HPV16 E7 antigen
or with a vaccinia virus vaccine encoding this E7 antigen
significantly increased the survival of TC-1 tumor-bearing
mice [74,75]. Interestingly, this effect has only been observed
when cisplatin was given before and not after the vaccination,
emphasizing the importance of timing of the given therapies
[74]. The combination induced significantly higher frequencies
of E7-specific CD8+ T-cells, both in blood and tumor, com-
pared to each treatment alone. Reason for this is that cisplatin
on one hand increases the expression of MHC class I on tumor
cells, thereby enhancing their susceptibility to be lysed by
specific CTLs and on the other hand, increases the influx of
intratumoral CD11c+ while decreasing the number of myeloid
suppressor cells and Tregs in blood and spleen [74,75].
Similarly, gemcitabine could also increase the percentage of
circulating monocytes, M1, and DCs [52,114]. Administration of
this chemotherapy alone or in poly-chemotherapy regimens
before immunotherapy may also enhance the clinical efficacy
through these mechanisms [62,114,115].
Similar observations have been made with low-dose radia-
tion 2 days before vaccination, although the highest frequency
of E7-specific CD8+ T-cells in tumor and spleen was reached
when radiation was given in combination with a second DNA
vaccination [64]. Moreover, in a phase I clinical study two
courses of cisplatin and 5-FU concurrent with radiotherapy
and before vaccination with a multiple epitope peptide vac-
cine increased the vaccine-specific CTL response in patients
with unresectable chemo-naïve esophageal squamous cell
carcinoma [61]. Thus, both chemotherapy and radiotherapy
or their combination (chemoradiation) given prior to vaccina-
tion can mediate immune stimulating and clinical effects.
In conclusion, there are a number of modalities that are
able to relief immune suppression as well as to condition the
immune system to optimally respond to immunotherapy.
Therefore, immunotherapy properly timed after these treat-
ments provides a platform to increase the clinical response of
patients to immunotherapy.
3.2. Concurrent combination of therapeutic modalities
with vaccination
3.2.1. Simultaneous combination of chemotherapy with
vaccination increases vaccine efficacy
Given the immune stimulatory capacity of certain che-
motherapeutic agents, administration of these cytotoxic
drugs not only before but also during vaccination can
result in improved antitumor responses. Concurrent admin-
istration of metronomic doses of cyclophosphamide in
combination with an HLA class I-binding survivin peptide
vaccine (DPX-Survivac) increased the antigen-specific
immune response. This was associated with the differentia-
tion of naïve T-cells into central/effector memory cells (CM/
EM) and late differentiated poly-functional antigen-specific
CD8+ T-cells in advanced ovarian cancer patients [76].
Similarly, metronomic administration of a high dose cock-
tail of chemotherapeutic agents (including cyclophospha-
mide, paclitaxel and docetaxel) during vaccination with a
multi-peptide cocktail of peptides (comprising hepatitis C
virus-derived antigens and tumor-associated antigens)
resulted in an enhanced specific T-cell response and a
reduced Treg frequency in hepatocellular carcinoma
(HCC) patients [79]. Coadministration of gemcitabine with
DC-based vaccines in a pancreatic carcinoma model
showed a synergistic antitumor effect [116]. Treatment of
patients with ovarian cancer with a p53 SLP vaccine in
combination with pegintron (pegylated IFNα) 7 days
before the first cycle of gemcitabine and repeated at day
22, during gemcitabine treatment, resulted in a strong
p53-specific T-cell response. In this study gemcitabine
treatment was associated with reduced levels of MDSCs,
and increased percentages of M1 macrophages,
circulating proliferating CD4+ and CD8+ T-cells but not
Tregs [80].
In addition, there are some reports suggesting that
immunotherapy may provide the correct environment for
chemotherapy to become more effective. In a poly-che-
motherapy regimen, administration of cyclophosphamide
or paclitaxel 1 day before and doxorubicin 7 days after
vaccination with GM-CSF-secreting tumor cells, enhanced
the antitumor efficacy of these chemotherapeutics in HER-
2/neu tolerized mice. Doxorubicin was provided to augment
the vaccine-induced antitumor efficacy but the mechanism
was unclear [77]. Potentially, immunotherapy operates via
increasing the number of cytokine-producing tumor-specific
T-cells thereby sensitizing tumor cells for chemotherapy-
induced cell death. In a HPV16 preclinical tumor model,
vaccination with HPV16 E6 and E7 SLPs combined with
cisplatin displayed a synergistic antitumor effect [81]. The
vaccination resulted in increased numbers of intratumoral
IFNγ and TNFα producing CD8+ T-cells. The TNFα produced
by these HPV-specific CD8+ T-cells not only had a direct
effect on tumor cell proliferation but also increased the
sensitivity of the tumor cells to cisplatin-induced tumor
cell death in a JNK-dependent fashion [81]. Thus, even at
this phase there is a place for chemotherapy to improve
vaccine-induced antitumor immunity.
3.2.2. Concurrent combination of immunomodulatory
antibodies with vaccination to curtail inhibitory immune
regulation
Another reasonable strategy to improve the efficacy and
maintenance of tumor-specific T-cell responses is by coun-
teracting immune regulation that acts when effector cells
start to express coinhibitory molecules as a normal response
to activation. Occasionally immunotherapy can alter the
EXPERT OPINION ON BIOLOGICAL THERAPY 95
tumor microenvironment or the expression of regulatory
molecules in a way that is not favorable for the therapeutic
outcome. Therefore, the appropriate combination of treat-
ments and the correct timing of each treatment modality
can be crucial for the final outcome. The demonstration of
high numbers of PD-1 and PD-L1 expressing CD8+ T-cells at
the invasive tumor margin and inside tumors of patients
with metastatic melanoma, suggested the application of
anti-PD-1 therapy in melanoma patients [117]. Indeed, treat-
ment with a multi-peptide tumor-epitope vaccine and PD-1
antibody (nivolumab) was well tolerated in patients with
resected high-risk metastatic melanoma. Furthermore,
immunological activity, such as increased antigen-specific
CD8+ T-cells but also increased frequencies of CD25+ or
CTLA-4+ CD4+ T-cells, was associated with promising survi-
val results [82]. Preclinical evidence has shown that TEGVAX
vaccine, which is an IFNγ-inducing cancer vaccine combined
with GM-CSF and TLR agonists, is associated with DC activa-
tion and an increase in the number of tumor-specific IFNγ-
producing tumor-infiltrating T-cells [83]. However, as a con-
sequence of this influx, cells in the tumor microenvironment
upregulate PD-L1 resulting in incomplete tumor cell elim-
ination. Furthermore, analysis of PBMCs following adminis-
tration of a glypcian-3 (GPC3) peptide vaccine in advanced
or metastatic HCC revealed a high expression of PD-1 on
peptide-specific CD8+ T-cells [84]. Similarly, immunotherapy
using Listeria monocytogenes (Lm)-LLO can be improved by
reduction of the Tregs and MDSCs, but as it is also asso-
ciated with the upregulation of PD-L1 on immune cells, in
particular macrophages, the use of antibodies blocking the
PD-1:PD-L1 axis is justified [85]. Indeed, administration of
the PD-1 blocking antibody in combination with the cancer
vaccine caused increased tumor regression. Another exam-
ple is the combined use of a cell-based GM-CSF-secreting
vaccine (GVAX) with CTLA-4 blocking antibody in an auto-
chronous prostate cancer model (Pro-TRAMP), which
enhanced the tumor antigen-specific CD4+ and CD8+ effec-
tor T-cells to Treg ratio and the tumor-antigen directed lytic
function [86]. Interestingly, the timing of administration of
the CTLA-4 blocking antibody greatly influenced the out-
come as the maximum effect has been observed when the
blocking antibody was applied after, but not before the
vaccination. The mechanism behind this crucially timed
application of the blocking antibody is that the GVAX vac-
cine not only increases tumor-specific CD8+ T-cells but also
upregulates the CTLA-4 expression on these effector cells,
thus by blocking this inhibitory molecule and its pathway
the effector function is not abrogated. Interestingly, in
patients with advanced small-cell lung cancer similar results
have been observed [118]. Administration of four doses of
ipilimumab after two doses of paclitaxel/carboplatin
improved the immune-related progression-free survival and
overall survival of patients compared to concurrent admin-
istration of ipilimumab and paclitaxel/carboplatin [118].
However, the detailed mechanisms still need to be investi-
gated. Thus, vaccination followed by specific treatments to
release the brakes on T-cells, instigated by coinhibitory
receptors, may form a powerful strategy to improve
tumor-specific T-cell efficacy.
In addition to coinhibitory receptor regulation, one might
also provide antibodies to known immune regulatory cyto-
kines or other (soluble) factors, which potentially can hamper
the induction of or weaken the antitumor immune response.
Among them are known tumor-derived factors such as VEGF,
transforming growth factor-β (TGFβ), prostaglandin E2 (PGE2),
IL-6, IL-10 and indoleamine-pyrrole 2,3-dioxygenase (IDO). For
instance, the combination of the standard therapy- Bacillus
Calmette-Guérin (BCG)- with a blocking anti-IL-10 receptor 1
monoclonal antibody (anti-IL10R1) resulted in enhanced anti-
tumor immunity by inducing Th1 immune response in bladder
cancer mouse model [87]. Therefore, these strategies to dam-
pen inhibitory immune regulation can be applied in combina-
tion or even after vaccination as will be described further in
this review.
3.3. Administration of therapeutic modalities after
vaccination
3.3.1. Combination of vaccines and immunomodulatory
antibodies enhances the antitumor response
To enhance antitumor immunity induced by vaccination, other
treatments such as agonistic antibodies to costimulatory
receptors on T-cells, the provision of cytokines and the stimu-
lation of antigen-presenting cells (APCs) by toll-like receptor
(TLR) agonists can play a major role as cotreatments. In these
cases the correct timing depends on the mechanism of action
of the immunomodulatory compound used, but most likely
they will be given in combination or after vaccination. Indeed,
immunization with vaccines that stimulate a broad immune
response and transfer of costimulatory agonist antibodies
potentially improves the antitumor response by enhancing
the T-cell response. Using DCs pulsed with apoptotic tumor
cells, which stimulate a broad immune response in Her-2/neu
mice, in combination with agonist anti-OX40 (CD134) or anti-
4-1BB (CD137) monoclonal antibodies showed substantial
tumor size reduction [89]. Mechanistically, administration of
these agonistic antibodies given 2 days after DC immunization
could improve the induced T-cell response as the effect of this
combined treatment is abrogated in the absence of CD4+ and
CD8+ T-cells. Likewise, combination of agonistic anti-4-1BB
one day after vaccination with tumor lysate-pulsed DCs follow-
ing another administration after 3 days enhanced tumor
regression in established pulmonary and subcutaneous
tumor models [88]. The rationale behind this therapeutic strat-
egy is that tumor lysate-pulsed DC vaccines induce transient
upregulation of 4-1BB on T-cells and NK cells in vaccine-
primed lymph nodes. Therefore, treatment with agonistic
4-1BB antibody could polarize effector T-cells towards a type
1 (IFNγ) response to tumor antigen in a CD4+, CD8+ and NK
cell dependent manner. In a similar fashion, treatment with
tumor lysate-pulsed DCs upregulate CD27 on T-cells in RM-1
prostate cancer tumor model and administration of CD27
agonistic antibodies after vaccination with these DCs could
reduce tumor outgrowth [78]. Thus, administration of immu-
nomodulatory compounds which stimulate DC or T-cell func-
tion, either by providing cytokines or costimulatory signals,
following vaccination strategies is a convenient way to pro-
mote the vaccine-induced antitumor efficacy.
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3.3.2. Postvaccination interventions to dampen the
immune regulatory response
Intervention drugs to abrogate the immune suppressive effect
of regulatory cytokines or molecules can be applied not only
in combination with vaccination but also after immunother-
apy. For instance, systemic blocking of TGFβ signaling after
vaccination with adenovirus expressing HPV-E7, or prior to
immunotherapy by adenovirus expressing IFN-β, increased
the antitumor efficacy compared to each treatment alone
[90]. TGFβ receptor blockade enhanced the intratumoral pro-
duction of immunostimulatory cytokines and chemokines as
well as the expression of ICAM-1 and led to the increased
infiltration of antigen-specific and functional CD8+ T-cells.
Another example is IDO, which catalyzes essential amino
acids such as tryptophan that are required for proliferation
and activation of immune cells, in particular T-cells. IDO is
overexpressed in tumor cells and tumor-associated APCs. To
improve the capacity of a DC-based vaccine, the IDO inhibitor
1-MT was administered after vaccination in a prophylactic
Lewis lung carcinoma murine model. Interestingly, IDO was
not expressed by tumor cells but only by the myeloid cells
within the tumor, tumor draining lymph nodes and spleen.
Moreover, a combination of the IDO inhibitor with other mod-
alities such as chemotherapy or blockade of coinhibitory mole-
cules, was shown to potentiate the antitumor efficacy of
therapy [119,120].
Postvaccination radiation may also aid by interfering with
immune regulating mechanisms. In a mouse colon adenocar-
cinoma tumor model of CEA, vaccination in a prime-boost
strategy with vaccinia and avipox recombinants, expressing
CEA and a triad of T-cell costimulatory molecules, in combina-
tion with local tumor irradiation induced synergistic antitumor
effects [91]. Radiation 3 days after vaccination induced upre-
gulation of the death receptor Fas on tumor cells, leading to
Fas/Fas ligand pathway mediated cell death. Therefore, the
combined treatment led to increased infiltration of T-cells and
CD4+ and CD8+ T-cell responses not only specific for CEA but
also for other overexpressed antigens in tumor. Similarly, local
radiation 5 days after vaccination with Shiga Toxin B-based
HPV vaccine in HPV-associated head and neck squamous cell
carcinoma induced synergistic tumor eradication in mice by
normalizing the tumor vasculature and thus improving tumor
infiltration by immune cells [92]. Thus, to improve the vaccine-
induced antitumor response one should also alleviate immune
regulatory mechanism that act after the activation of tumor-
specific T-cells.
4. Immunoguiding is important for the development
of immunotherapeutic strategies
The increasing reports on the immune modulatory properties
of chemotherapy and radiotherapy, the debate on the exact
working mechanism of CTLA-4-blocking antibodies [121–123]
and the unexpected outcomes of myeloid cell depletion by
CSF1R inhibition during immunotherapy [58,124] exemplify
the need for immunomonitoring studies that analyze the
effect of drugs on the immune system, and in particular
beyond the expected mechanisms of action. This
immunological knowledge then can be used to guide the
rational design of combination therapies, which in the past
were more based on empirical testing [23,95]. It is well known
that there are many immunological differences between all
the different animal models used – and sometimes even
between what used to be the same tumor cell lines – to
develop immunotherapy. Moreover, the number of analyses,
required to study the many permutations possible, is too high
for single consortia to address. Therefore, an important aspect
is to ensure that the measurement and reporting of the results
obtained are comparable between laboratories so that it is
easier to interpret and value the data generated. In the last
decade a huge effort, undertaken by the Association of Cancer
ImmunoTherapy’s (CIMT’s) immunoguiding program [125] and
Cancer Immunotherapy Consortium (CIC) [126], has focused
on this in the realm of human studies, and this has successfully
led to: (i) a strong awareness of the need to harmonize or
standardize measurements, (ii) to technical improvements and
harmonization of the assays used, and (iii) to more transparent
reporting [127–129]. It can be envisaged that similar efforts by
scientists performing studies in mouse tumor models will lead
to a quicker design of immunotherapeutic strategies, which
expedite the translation to the treatment of patients.
5. Conclusions
In conclusion, the field is moving rapidly towards understand-
ing the requirements for optimal immunotherapy of cancer.
Combinations of treatment modalities are designed and
tested to accommodate the most effective tumor-specific
immune response. Surgery, chemotherapeutic compounds,
radiotherapy schedules, antibodies and targeted therapies
have successfully been administrated before applying immu-
notherapy with the aim to reduce immunosuppressive cells, or
during and after immunotherapy to potentiate the immune
response and to prevent immune regulation. A full under-
standing of the immunological effects of the compounds
used, their pharmacological dynamics, and the optimal
sequence during treatment will result in clinical benefit for
the majority of patients.
6. Expert opinion
Cancer may be cured by immunotherapy but the develop-
ment of cancer is associated with increased immune suppres-
sion. Furthermore, the induction of tumor-specific immunity
is difficult and regulated afterwards. Hence, for an optimal
antitumor response it is important to provide the most
appropriate therapeutic modality at the right time. The dif-
ferent schedules and various modalities, and combinations
thereof, have been discussed in this review and are recapitu-
lated in Figure 1. In our opinion, the prevention of tumor
development in high-risk patients, treatment of premalignant
lesions or prevention of recurrences after curative treatments,
is the ideal time period to stop cancer and vaccines are ideal
to induce protective tumor-specific immunity. However, in
general practice immunotherapy is applied to cancer patients
with more advanced stage of disease, and as such its success
is determined by the level of immunosuppression
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encountered in microenvironment. The treatment of prema-
lignant lesions [3,33], but certainly that of patients with can-
cer, demonstrates that the increase in general and local
immune suppression requires additional modalities to curtail
these suppressive mechanisms and to optimally activate and
expand tumor-specific T-cells. At this phase a correct
sequence and interval of drugs is essential, as it will be
required to use prime combinations of several modalities to
obtain clinical success in the majority of patients. Based on
the observations in mouse tumor models and in patients it is
clear that myeloid suppressor cells and Tregs stifle the induc-
tion of a strong and effective antitumor response and that
alleviation of this immune suppression is required before the
activation of the antitumor T-cell response. In addition, extra
support is needed to ensure the strong expansion and appro-
priate effector function of the tumor-specific T-cells. Finally,
as the activated effector T-cells will start to express coinhibi-
tory molecules, the ligands of which can be expressed at the
tumor site or will be as a consequence of T-cell produced
IFNγ, there is a need to counteract immune regulation at this
point during therapy. As described in this review, for each of
the stages (before, during and after vaccination) help can be
provided via either surgical tumor reduction, chemotherapy,
radiation therapy and/or a number of other immune modu-
lators. However, before such combinations are designed it
will be essential to establish the dynamics and exact immune
modulatory properties of the agents used. Chemotherapeutic
agents may affect different immune cell populations and this
effect may be transient [48]. While its seems logical to under-
stand the dynamics and immune modulating properties of
chemotherapeutic compounds, this is also required for other
compounds such as targeted therapy of macrophages
[58,124] and antibodies targeting costimulatory and coinhibi-
tory molecules. This is well illustrated by different timing
schedules of anti-CTLA-4 and anti-OX40 in a murine color-
ectal carcinoma model in combination with radiation therapy
[130]. Antibodies against CTLA-4 and OX40 can only improve
the survival of tumor bearing mice when applied before and
after radiation therapy, respectively. Therefore, not only the
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Figure 1. Illustration of different timing schedules of various therapies in combination with immunotherapy based on their mechanisms. The individual examples of
each combination therapy are summarized in Table 1. The colour gradients show the time points (prior, concurrent and/or after immunotherapy) at which the
therapies are mostly applied. The blue box shows the therapies which are mostly applied prior to immunotherapy and less often concurrent with immunotherapy.
The orange box shows the therapies which are often applied concurrent with immunotherapy and less after immunotherapy. The green box shows the therapies
which are used mainly after immunotherapy and less concurrent with immunotherapy. Abbreviations: Tregs: Regulatory T-cells, MDSC: Myeloid-derived suppressor
cells, M2 macrophages: type 2 macrophages, DC: dendritic cell.
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sequence of administration should be tested and considered
in the design of the most optimal combined-therapeutic
strategy. The drawbacks of this approach of course are the
costs and the time needed to perform these interrogations
with as result that such well-designed studies are scarce, but
they are coming. Immunomonitoring is an extremely impor-
tant aspect in understanding these matters. It should be
applied in the broadest sense, certainly not restricted to the
expected mechanism of action, and also take into account
(unexpected) negative effects of the treatment. As many of
the studies will be performed (only) in mouse models it
becomes important that laboratories using mouse models
will focus on increasing the comparability of immunomoni-
toring and reporting of results, similar to current efforts in the
monitoring of human immune responses. Notably, one
should be aware that while we can learn a lot from murine
experiments, they still not fully reflect the human situation.
Therefore, effort should be undertaken to properly investi-
gate the sequence and timing of the most promising combi-
nations in clinical studies. Fortunately, the field is moving
forward towards rationally designed combination therapy
and a better understanding of the patient population that is
to be treated. Finally, we envisage that the ideal combination
aims to: (1) increase the number of tumor-specific T-cells; (2)
prevent their subsequent regulation in the tumor bed; (3)
decrease the number of immune suppressive myeloid cells
and Tregs; and (4) activate intratumoral antigen presenting
cells. In theory, this should lead to major improvements in
clinical outcome, well above the levels that is currently
reached.
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